Citigroup Inc. Has $13.68 Million Stock Holdings in Exelixis, Inc. $EXEL

Citigroup Inc. decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 52.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 331,279 shares of the biotechnology company’s stock after selling 365,552 shares during the quarter. Citigroup Inc.’s holdings in Exelixis were worth $13,682,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Rossby Financial LCC boosted its position in shares of Exelixis by 131.2% during the third quarter. Rossby Financial LCC now owns 6,820 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 3,870 shares in the last quarter. Hillsdale Investment Management Inc. raised its stake in Exelixis by 22.2% during the 3rd quarter. Hillsdale Investment Management Inc. now owns 100,600 shares of the biotechnology company’s stock worth $4,155,000 after buying an additional 18,300 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Exelixis during the third quarter worth about $350,000. Jupiter Asset Management Ltd. grew its stake in Exelixis by 99.3% in the third quarter. Jupiter Asset Management Ltd. now owns 2,111,933 shares of the biotechnology company’s stock valued at $87,223,000 after acquiring an additional 1,052,008 shares during the period. Finally, NewEdge Wealth LLC increased its holdings in shares of Exelixis by 22.9% in the third quarter. NewEdge Wealth LLC now owns 25,439 shares of the biotechnology company’s stock worth $1,027,000 after acquiring an additional 4,745 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In related news, CFO Christopher J. Senner sold 30,617 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total transaction of $1,337,044.39. Following the transaction, the chief financial officer directly owned 976,092 shares in the company, valued at approximately $42,625,937.64. The trade was a 3.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jack L. Wyszomierski sold 99,574 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the sale, the director directly owned 279,942 shares in the company, valued at $12,320,247.42. This trade represents a 26.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 362,849 shares of company stock worth $15,917,463 in the last quarter. 2.82% of the stock is owned by company insiders.

Exelixis Price Performance

Shares of NASDAQ EXEL opened at $44.06 on Friday. The business has a 50-day moving average of $44.09 and a 200-day moving average of $41.44. The stock has a market capitalization of $11.44 billion, a price-to-earnings ratio of 15.91, a PEG ratio of 1.00 and a beta of 0.42. Exelixis, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.55 earnings per share. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on EXEL. Royal Bank Of Canada lifted their price objective on Exelixis from $45.00 to $46.00 and gave the company a “sector perform” rating in a report on Wednesday, February 11th. Wells Fargo & Company lifted their price target on shares of Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Zacks Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Truist Financial set a $51.00 price objective on shares of Exelixis in a research report on Wednesday, January 14th. Finally, Bank of America cut Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price for the company. in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.11.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.